Cancer profiling is an advanced technique used to identify tumors more accurately, by determining genomic alteration, which supports to select appropriate therapy for the treatment of cancer. Moreover, this technique decreases the trial and error during the process in the diagnosis of cancer at various stages and provide more precise and accurate information about clinical […]
Cancer Profiling Market Insights: Trends, Growth, and Key Players 2021-2026
Cancer profiling is an advanced technique used to identify tumors more accurately, by determining genomic alteration, which supports to select appropriate therapy for the treatment of cancer. Moreover, this technique decreases the trial and error during the process in the diagnosis of cancer at various stages and provide more precise and accurate information about clinical outcomes of cancer. Laboratory test (blood and urine), biopsy, imaging test (X-ray, MRI, PET/CT, and ultrasound), nuclear medicine scan, and lumbar puncture, are some of the tests used to diagnose cancer which is unable to identify the exact cause of cancer in early stages.
According to the World Health Organization (WHO), nearly 1 in 6 deaths occurs due to cancer and around 8.8 million people died from cancer worldwide in 2015. Increasing incidence and prevalence of different cancers among individuals augmented the demand for accurate diagnosis of cause in the early stage of cancer.
Get Your Sample Copy of the Cancer/Tumor Profiling Market Report 2021
Introduction of cancer profiling over traditional cancer diagnostic procedure is expected to gain growth of the Cancer/Tumor profiling market
St. Jude Medical Center’s Crosson Cancer Institute has joined Caris’ Precision Oncology Alliance (POA) as its 17th member in 2017. POA is established by Caris Life Sciences to promote the appropriate use of the molecular tools in the diagnosis and treatment of cancer. The St. Jude Medical Center’s Crosson Cancer Institute will help Caris Life Sciences to develop standard and best practices to make cancer treatment more effective and precise by advancing the use of tumor profiling.
EpiVax Inc. launched EpiVax Oncology Inc., which is an approach for precision cancer immunotherapy in 2017. EpiVax used molecular profiling through Next-Generation Sequencing (NGS) to produce therapeutic vaccines for cancer.
Personal Genome Diagnostics Inc. has introduced CancerSELECT 125 test for pan-cancer tumor profiling in 2016. CancerSELECT 125 identify tumor-specific functional sequence mutation in multiple cancer types with high accuracy.
Rising prevalence of cancer and growing demand for accurate diagnosis of cancer in the early stage is projected to fuel the growth of cancer profiling market
According to a report by American Cancer Society (ACS), in 2016, around 1,685,210 new cases of cancer were diagnosed and around 595,690 cancer deaths were estimated in U.S. Moreover, according to the World Cancer Research Fund International (WCRFI), in 2012, around 14.1 million cancer cases were estimated worldwide, in which, around 7.4 men and 6.6 million female diagnosed. As per WCRFI, it is predicted that by 2035, world-widely around 24 million cancer cases will raise.
Moreover, according to Cancer Research UK, around 356,860 new cases of cancer were diagnosed in 2014, in which most common cancers were breast, prostate, and lung or bowel cancer. The data represent increasing incidence and prevalence of cancer globally which is further expected to fuel the demand for cancer profiling.
Rising awareness of cancer by many organization and foundations at local, state and global level include Cancer Preventive Program by WHO, National Cancer Control Program, and Prevent Cancer Foundation, expected to fuel the growth of cancer profiling market in the near future.
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/967
Cancer/Tumor Profiling Market – Competitive Landscape
Some of the major key players operating in the global cancer profiling market include Proteome Sciences PLC, Life Technologies Corporation, Illumina, Inc., BioTheranostics, RiboMed Biotechnologies Inc., NeoGenomics Laboratories, Oxford Gene Technology Ltd., Genomic Health Inc., Agendia, and Oncopath Laboratories.
Key Developments
In May 2019, QIAGEN, launched therascreen PIK3CA RGQ PCR Kit after it received (USFDA) regulatory approval as a companion diagnostic to aid in identifying breast cancer patients.
In May 2019, NeoGenomics Laboratories collaborated with QIAGEN to offer companion diagnostic test for HR+/HER2 for advanced breast cancer patients to detect PIK3CA mutation using QIAGEN’s therascreen PIK3CA RGQ PCR test.
In May 2018, ILLUMINA, Inc., acquired Edico Genome, a leading provider of data analysis acceleration solutions for next-generation sequencing (NGS) to accelerate genomic data analysis.
In August 2018, HTG molecular diagnostic, Inc. agreed with Oncologie Inc., where the companies have agreed to partner on the development of biomarkers associated with Oncologie’s Immuno-oncology pipeline.
In October 2016, Personal Genome Diagnostics Inc., one of the leading providers of advanced cancer genome testing products and services, launched PlasmaSELECT 64 targeted panel for pan-cancer tumor profiling. PlasmaSELECT 64 identifies clinically actionable and functionally important sequence mutations and structural alterations across multiple cancer types without the need for invasive biopsies
Cancer/Tumor Profiling Market -Taxonomy
By Technology
- Microarray
- Next-Generation Sequencing (NGS)
- Quantitative Polymerase Chain Reaction (QPCR)
- Immunohistochemistry (IHC)
- In Situ Hybridization (ISH)
- Fluorescence In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization (CISH)
By Technique
- Genomics
- Proteomics
- Epigenetics
- Metabolomics
By Application
- Diagnostics
- Personalized Medicine
- Biomarker Discovery
- Prognostics
- Others (Research Applications)
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Cancer/Tumor Profiling Market Size and Share 2021 | Future Trends, Growth Analysis, Top Manufacturers and Regional Insights, Forecast To 2026 appeared first on Gatorledger.
